These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26793998)

  • 1. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
    Saenz-de-Viteri M; Fernández-Robredo P; Hernández M; Bezunartea J; Reiter N; Recalde S; García-Layana A
    Biochem Pharmacol; 2016 Mar; 103():129-39. PubMed ID: 26793998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Bevacizumab, Ranibizumab, and Aflibercept on MicroRNA Expression in a Retinal Pigment Epithelium Cell Culture Model of Oxidative Stress.
    Dinç E; Ayaz L; Kurt AH
    J Ocul Pharmacol Ther; 2018 May; 34(4):346-353. PubMed ID: 29389239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.
    Schnichels S; Hagemann U; Januschowski K; Hofmann J; Bartz-Schmidt KU; Szurman P; Spitzer MS; Aisenbrey S
    Br J Ophthalmol; 2013 Jul; 97(7):917-23. PubMed ID: 23686000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
    Sheu SJ; Chao YM; Liu NC; Chan JY
    Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept.
    Ranjbar M; Brinkmann MP; Zapf D; Miura Y; Rudolf M; Grisanti S
    Cell Physiol Biochem; 2016; 38(2):737-47. PubMed ID: 26871551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T
    Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.
    Malik D; Tarek M; Caceres del Carpio J; Ramirez C; Boyer D; Kenney MC; Kuppermann BD
    Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i11-16. PubMed ID: 24836865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.
    Puddu A; Sanguineti R; Traverso CE; Viviani GL; Nicolò M
    Eur J Ophthalmol; 2016 Aug; 26(5):425-30. PubMed ID: 27079208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
    Chae JB; Rho CR; Shin JA; Lyu J; Kang S
    Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
    Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
    Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective Effect of Combined Caffeic Acid Phenethyl Ester and Bevacizumab Against Hydrogen Peroxide-Induced Oxidative Stress in Human RPE Cells.
    Dinc E; Ayaz L; Kurt AH
    Curr Eye Res; 2017 Dec; 42(12):1659-1666. PubMed ID: 28937872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione.
    Miura Y; Klettner A; Roider J
    Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4848-55. PubMed ID: 20435596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aflibercept and Ranibizumab Modulate Retinal Pigment Epithelial Cells Function by Acting on Their Cross Talk with Vascular Endothelial Cells.
    De Cillà S; Farruggio S; Cocomazzi G; Mary D; Alkabes M; Rossetti L; Vujosevic S; Grossini E
    Cell Physiol Biochem; 2020 Feb; 54(2):161-179. PubMed ID: 32045141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis.
    Klettner A; Tahmaz N; Dithmer M; Richert E; Roider J
    Br J Ophthalmol; 2014 Oct; 98(10):1448-52. PubMed ID: 25034050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria.
    Vo TA; Abedi S; Schneider K; Chwa M; Kenney MC
    Exp Eye Res; 2018 Dec; 177():112-116. PubMed ID: 30071215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
    Klettner A; Recber M; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy.
    De Cillà S; Farruggio S; Vujosevic S; Raina G; Filippini D; Gatti V; Clemente N; Mary D; Vezzola D; Casini G; Rossetti L; Grossini E
    Cell Physiol Biochem; 2017; 42(5):1725-1738. PubMed ID: 28743128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of VEGF inhibitors on human retinal pigment epithelium under high glucose and hypoxia.
    Bahrami B; Shen W; Zhu L; Zhang T; Chang A; Gillies MC
    Clin Exp Ophthalmol; 2019 Nov; 47(8):1074-1081. PubMed ID: 31265210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.